Charles River Laboratories (CRL) Tops Q4 EPS by 6c

Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.49, $0.06 better than the analyst estimate of $2.43. Revenue for the quarter came in at $905.1 million versus the consensus estimate of $888.31 million.

Reaffirms 2022 Guidance

The Company is reaffirming its 2022 financial guidance, which was originally provided on January 11, 2022. As previously mentioned, the Company expects to benefit from a continuation of the robust client demand that it experienced last year and price increases, which is expected to drive low-teens revenue growth in 2022. On a non-GAAP basis, earnings per share growth in 2022 is expected to be similar to revenue growth, as modest operating margin improvement will be largely offset by less favorable below-the-line items, including a higher tax rate.

The Company’s 2022 guidance for revenue growth, earnings per share, and cash flow is as follows:

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Energy Fuels to acquire rare earth magnet maker VAC for $1.9 billion
• NVE Corporation names new CEO and expands board to seven members